Review article · 2021 · Open access

The clinical advances of proteolysis targeting chimeras in oncology

Hao Xie, Junjia Liu, Diego Alem, Jason B. Fleming

Exploration of Targeted Anti-tumor Therapy, 2(6), 511–521 · Published 2 December 2021 · DOI 10.37349/etat.2021.00061

Open PDFView at the publisherCite this paper

In brief

“The clinical advances of proteolysis targeting chimeras in oncology” is a 2021 review article by Hao Xie and 3 co-authors, published in Exploration of Targeted Anti-tumor Therapy. OpenAlex counts 40 citations as of 21 November 2026, which puts it in the top 2% of works published in 2021 by citations. It is open access under a CC BY licence: the full text is free to read at Exploration of Targeted Anti-tumor Therapy.

Citations
40
Most cited in
2024 (10)
Field-weighted impact
0.63
References
45
Authors
4

Abstract

Proteolysis targeting chimeras (PROTACs) are a class of small molecules designed to target proteins for degradation. Their novel and unique modes of action provide PROTACs with the potential for their application in the management of both solid and hematologic malignancies. Since its initial discovery, the technology of targeted protein degradation, especially in the form of PROTACs, has had significant advances. A number of PROTACs have entered a late stage of preclinical development. Several of them are either in phase 1/2 clinical trials or approaching approval for initial clinical evaluation. This article discusses the preclinical and clinical findings of PROTACs of clinically relevant protein targets in cancer.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Xie, H., Liu, J., Alem, D., & Fleming, J. B. (2021). The clinical advances of proteolysis targeting chimeras in oncology. Exploration of Targeted Anti-tumor Therapy, 2(6), 511–521. https://doi.org/10.37349/etat.2021.00061

MLA 9

Xie, Hao, et al. “The clinical advances of proteolysis targeting chimeras in oncology.” Exploration of Targeted Anti-tumor Therapy, vol. 2, no. 6, 2021, pp. 511–521. https://doi.org/10.37349/etat.2021.00061.

Chicago

Xie, Hao, Junjia Liu, Diego Alem, and Jason B. Fleming. 2021. “The clinical advances of proteolysis targeting chimeras in oncology.” Exploration of Targeted Anti-tumor Therapy 2 (6): 511–521. https://doi.org/10.37349/etat.2021.00061.

Harvard

Xie, H. et al. (2021) ‘The clinical advances of proteolysis targeting chimeras in oncology’, Exploration of Targeted Anti-tumor Therapy, 2(6), pp. 511–521. doi:10.37349/etat.2021.00061.

IEEE

H. Xie, J. Liu, D. Alem, and J. B. Fleming, “The clinical advances of proteolysis targeting chimeras in oncology,” Exploration of Targeted Anti-tumor Therapy, vol. 2, no. 6, pp. 511–521, 2021, doi: 10.37349/etat.2021.00061.

BibTeX

@article{xie2021clinical,
  title     = {{The clinical advances of proteolysis targeting chimeras in oncology}},
  author    = {Xie, Hao and Liu, Junjia and Alem, Diego and Fleming, Jason B.},
  journal   = {Exploration of Targeted Anti-tumor Therapy},
  year      = {2021},
  volume    = {2},
  number    = {6},
  pages     = {511--521},
  doi       = {10.37349/etat.2021.00061},
  url       = {https://doi.org/10.37349/etat.2021.00061}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202288
202388
20241010
202577
202677

Its field-weighted citation impact is 0.63: it has been cited 0.63 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • PROTACs
  • targeted protein degradation
  • cancer therapy
  • solid tumors
  • hematologic malignancies
  • clinical trials
  • preclinical drug development
  • protein degradation

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Xie, H., Liu, J., Alem, D., & Fleming, J. B. (2021). The clinical advances of proteolysis targeting chimeras in oncology. Exploration of Targeted Anti-tumor Therapy, 2(6), 511–521. https://doi.org/10.37349/etat.2021.00061

How many times has this paper been cited?

40 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Exploration of Targeted Anti-tumor Therapy: sign in and open the PDF from this page.

Who wrote this paper?

Hao Xie, Junjia Liu, Diego Alem, Jason B. Fleming.

What is the DOI of this paper?

10.37349/etat.2021.00061, permanently at https://doi.org/10.37349/etat.2021.00061. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.